News / University of Bristol

Bristol University spin-out secures seed funding 

By Ellie Pipe  Tuesday Sep 27, 2022

A biotech firm that is working to tackle a condition that affects 6.8m people worldwide is preparing to launch its product on the market.

Ferryx is a University of Bristol spin-out that has secured £300,000 of seed funding to develop its innovative treatment for gut inflammation.

The startup founders say that while the condition – known in one form as inflammatory bowel disease – affects millions of people, there is a lack of satisfactory treatments, leaving sufferers reliant on medications with significant negative side effects.

Better Business
Better Business is an initiative launched by Bristol24/7 to help businesses thrive, whilst creating a positive impact on Bristol and the people who live here.

The lead product developed by the Future Space-based company is a probiotic called FX856 with demonstrated anti-inflammatory properties that survives and thrives during active inflammation. Currently, there is no available probiotic that can function during periods of active inflammation.

https://twitter.com/ferryx_bristol/status/1410624046723735559

The company’s CEO Dr Jenny Bailey says the funding from Deepbridge has come at a “pivotal time” for Ferryx.

Bailey said: “We are delighted to be working with Deepbridge. Their expertise in the life sciences sector adds significant value to this investment and we feel that they are our ideal partners at this pivotal time as we look to launch our first product and work towards clinical trials.”

Ben Carter, investment director and head of life sciences at Deepbridge Capital, added: “Jenny and the team at Ferryx absolutely represent the inspiring innovators that we look for in early-stage life sciences companies. We are delighted to be supporting another great university spin-out in the burgeoning UK life sciences sector.”

Ferryx has secured £300,000 of seed funding to develop its innovative treatment for gut inflammation – photo: Ferryx/ Green Target PR

Ferryx is preparing for the launch of FX856 as a food supplement product, whilst simultaneously preparing to take the product through a clinical trial in patients with inflammatory bowel disease.

Main photo: Ferryx/ Green Target PR

Read more: 

Listen to the latest Bristol24/7 Behind the Headlines podcast:

Our top newsletters emailed directly to you
I want to receive (tick as many as you want):
I'm interested in (for future reference):
Marketing Permissions

Bristol24/7 will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

We will only use your information in accordance with our privacy policy, which can be viewed here - www.bristol247.com/privacy-policy/ - you can change your mind at any time by clicking the unsubscribe link in the footer of any email you receive from us, or by contacting us at meg@bristol247.com. We will treat your information with respect.


We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices here.

Related articles

You've read %d articles this month
Consider becoming a member today
Independent journalism
is needed now More than ever
You've read %d articles this month
Consider becoming a member today
You've read %d articles this month
Consider becoming a member today
Join the Better
Business initiative
You've read %d articles this month
Consider becoming a member today
* prices do not include VAT
You've read %d articles this month
Consider becoming a member today
Enjoy delicious local
exclusive deals
You've read %d articles this month
Consider becoming a member today
Wake up to the latest
Get the breaking news, events and culture in your inbox every morning